Recent advances in selective alpha1-adrenoreceptor antagonists as antihypertensive agents.
Hypertension is one of the most serious health problems of the modern world with a continuous rise in the number of patients. Selective alpha(1)-adrenoreceptor antagonists though have many advantages and uses in the management of arterial hypertension, their lack of specificity at the level of alpha(1)-adr subtypes leads to multiple side effects. Existence of multiple alpha(1)-adr subtypes holds great promise for the discovery and development of more specific and selective drug molecules, targeting only one alpha(1)-adr subtype at a time and thus relative freedom from side effects. Herein, the research done on the discovery and evaluation of a variety of chemically diverse structures as selective antagonists of alpha(1)-adr and alpha(1)-adr subtypes in recent years has been reviewed.
Jain
Kishor S
KS
Sinhgad College of Pharmacy, Pune 411041, India. kishor.s.jain@gmail.com
Bariwal
Jitender B
JB
Kathiravan
Muthu K
MK
Phoujdar
Manisha S
MS
Sahne
Rajkumari S
RS
Chauhan
Bishram S
BS
Shah
Anamik K
AK
Yadav
Mange Ram
MR
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000959:Antihypertensive Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D015394:Molecular Structure; D018340:Receptors, Adrenergic, alpha-1 / Q000145:classification; D012307:Risk Factors; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D018340:Receptors, Adrenergic, alpha-1